ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,584.54
-0.88%
US Tech 100
19,681.20
-2.17%
Dow Jones
39,753.75
0.08%
Brent Oil
85.325
0.25%
Bitcoin
57,486.31
0.24%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Gossamer Bio Inc (GOSS) Quote

Gossamer Bio Inc

Gossamer Bio Inc (GOSS)

NASDAQ
1.23
0.06
(5.13%)
Closed July 11 4:00PM
Delayed by 15 minutes
1.30
0.07
(5.69%)
After Hours: 7:53PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.30
Bid
1.24
Ask
1.31
Volume
3,215,013
1.155 Day's Range 1.37
0.4525 52 Week Range 1.88
Market Cap
264.676M
Previous Close
1.17
Open
1.19
Last Trade
10
@
1.27
Last Trade Time
Financial Volume
$ 4,115,093
VWAP
1.28
Average Volume (3m)
2,438,847
Shares Outstanding
226,218,652
Dividend Yield
-
PE Ratio
-1.55
Earnings Per Share (EPS)
-0.79
Revenue
-
Net Profit
-179.82M

About Gossamer Bio Inc

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth,... Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.gossamerbio.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Gossamer Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GOSS. The last closing price for Gossamer Bio was $1.17. Over the last year, Gossamer Bio shares have traded in a share price range of $ 0.4525 to $ 1.88.

Gossamer Bio currently has 226,218,652 shares outstanding. The market capitalization of Gossamer Bio is $264.68 million. Gossamer Bio has a price to earnings ratio (PE ratio) of -1.55.

GOSS Latest News

More News

Form 8-K - Current report

June 10 2024
Edgar (US Regulatory)

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

June 07 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

June 06 2024
Edgar (US Regulatory)

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

May 14 2024
Business Wire

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

May 10 2024
Business Wire

Form 8-K - Current report

May 07 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 07 2024
Edgar (US Regulatory)

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

- Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD...

May 07 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.33011.37120410991.15858949CS
40.771145.7466918710.5291.370.510443327380.80048397CS
120.4858.53658536590.821.370.499324388470.75025008CS
260.3232.65306122450.981.60.499317884760.90600325CS
52-0.19-12.75167785231.491.880.452519517850.92324987CS
156-6.84-84.02948402958.1415.1950.452519246203.45526901CS
260-19.79-93.835941204421.0927.14970.452513868365.05041554CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LCFYLocafy Ltd
$ 6.10
(162.92%)
46.08M
KZIAKazia Therapeutics Ltd
$ 1.24
(85.57%)
215.06M
CYNCYNGN Inc
$ 7.20
(81.82%)
17.89M
NEXINexImmune Inc
$ 3.84
(66.23%)
34.48M
BDRXBiodexa Pharmaceuticals PLC
$ 1.08
(51.88%)
59.99M
CETUUCetus Capital Acquisition Corporation
$ 7.00
(-29.72%)
1.42k
TRIBTrinity Biotech PLC
$ 2.046
(-28.96%)
81.02k
CINGCingulate Inc
$ 0.4845
(-25.23%)
1.33M
IVPInspire Veterinary Partners Inc
$ 5.5842
(-24.54%)
2.35M
SLRXSalarius Pharmaceuticals Inc
$ 2.12
(-22.70%)
1.99M
NVDANVIDIA Corporation
$ 127.40
(-5.57%)
362.02M
MAXNMaxeon Solar Technologies Ltd
$ 0.24
(13.85%)
349.82M
TSLATesla Inc
$ 241.03
(-8.44%)
217.69M
KZIAKazia Therapeutics Ltd
$ 1.24
(85.57%)
215.06M
SQQQProShares UltraPro Short QQQ
$ 7.63
(6.42%)
178.49M

GOSS Discussion

View Posts
georgie18 georgie18 8 hours ago
GOSS...$1.31....HOD...Off the .66 range bottom...🥳
👍️0
georgie18 georgie18 1 day ago
GOSS...$1.25...Off the .66 Range Bottom...🥳
👍️0
TechandBio TechandBio 1 day ago
Gossamer Nice 178% move from where I got in regret not buying more a win is a win. Rivian and ICCM accumulating..
$GOSS
👍️0
georgie18 georgie18 2 days ago
GOSS...$1.20...Getting hits into the close...🥳
👍️0
georgie18 georgie18 2 days ago
GOSS...$1.17...Trying Red to Green here...🥳
👍️0
georgie18 georgie18 3 days ago
GOSS...$1.15...slowly creeping up off the .50 range bottom...🥳
👍️0
georgie18 georgie18 3 days ago
GOSS...$1.10...Red to Green here...🥳Off the .50 range bottom...
👍️0
Monksdream Monksdream 5 days ago
GOSS under $2
👍️0
georgie18 georgie18 6 days ago
GOSS...$1.04... https://schrts.co/QnRKixhB ...🥳...Looking for the $1.09 Break and a move to $1.60 plus range...Off the .50 range bottom...
👍️0
georgie18 georgie18 2 weeks ago
GOSS...9348...Trying red to green here off THE 200MA Bounce...🥳
👍️0
georgie18 georgie18 2 weeks ago
GOSS...$1.02...on the 100/200MA Break...🥳...If this holds then we have a double top to break $1.60 range...
👍️0
georgie18 georgie18 2 weeks ago
GOSS...939...🥳in the P/M...
👍️0
glenn1919 glenn1919 2 weeks ago
GOSS................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783
👍️0
georgie18 georgie18 2 weeks ago
GOSS...86...Perhaps we see the Break/Hold of the 100MA at .93...🥳
👍️0
georgie18 georgie18 2 weeks ago
GOSS...755...🥳...on the upper bollie Break...Break/Hold .87 and we have a runner...imo...we shall see...
👍️0
Pennyhero Pennyhero 2 weeks ago
Ready for take off! 🚀🚀🚀
👍️0
georgie18 georgie18 2 weeks ago
GOSS...71s clearing here...🥳
👍️0
georgie18 georgie18 3 weeks ago
GOSS...673...Trying for the 50MA Breakout here...🥳
👍️0
georgie18 georgie18 3 weeks ago
GOSS...66...on the Upper Bollie Break...🥳
👍️0
Termite7 Termite7 2 months ago
Assuming phase 3 approval, what price? Thanks!!!
👍️0
FlippinNDippin FlippinNDippin 3 months ago
Took a starter here. GLTA
👍️0
Monksdream Monksdream 4 months ago
GOSS under $2
👍️0
glenn1919 glenn1919 4 months ago
GOSS..........................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 5 months ago
GOSS..................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 5 months ago
GOSS......................................https://stockcharts.com/h-sc/ui?s=GOSS&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 months ago
GOSS under $2
👍️0
Monksdream Monksdream 10 months ago
GOSS new 52 week low
👍️0
Monksdream Monksdream 10 months ago
GOSS new 52 week low
👍️0
Monksdream Monksdream 10 months ago
GOSS new 52 week low
👍️0
Dutch4 Dutch4 1 year ago
Agreed!
👍️0
hippityhop hippityhop 2 years ago
Institutionals shorting this unmercilessly. Three trades totalling 2.4M total shares bought at 4 pm. @ .20 cent profit a share come to $468k.
👍️0
hippityhop hippityhop 2 years ago
This is a 100/200 percenter in next 3 months, buy this now or weep later!!
👍️0
crudeoil24 crudeoil24 2 years ago
Raymond James Initiates Coverage On Gossamer Bio with Outperform Rating, Announces Price Target of $19
7:13 am ET April 18, 2022 (Benzinga) Print
Raymond James analyst Timur Ivannikov initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announces Price Target of $19.

Latest Ratings for GOSS DateFirmActionFromTo

Nov 2021SVB LeerinkMaintainsOutperform Aug 2021SVB LeerinkMaintainsOutperform Mar 2021HC Wainwright & Co.ReiteratesBuy
👍️0
crudeoil24 crudeoil24 2 years ago
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company's product candidates include Seralutinib (GB002), GB004, GB5121 and GB7208. GB002 is an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R) and c-KIT inhibitor in development for the treatment of pulmonary arterial hypertension (PAH). GB004 is a gut-targeted, oral small molecule being developed for the treatment of inflammatory bowel disease (IBD). GB5121 is an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), in clinical development for the treatment of primary central nervous system lymphoma (PCNSL). GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis (MS).
👍️0

Your Recent History

NASDAQ
GOSS
Gossamer Bio
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved